Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study

CONCLUSIONS: Lenvatinib shows no significant difference in response between patients with and without viral infection. Treatment strategies based on the etiology of liver disease may lead to good clinical outcome.PMID:34515171 | DOI:10.1159/000517494

Source: Oncology - September 13, 2021 Category: Cancer & Oncology Authors: Takeshi Hatanaka Satoru Kakizaki Tamon Nagashima Masashi Namikawa Takashi Ueno Hiroki Tojima Daichi Takizawa Atsushi Naganuma Hirotaka Arai Norifumi Harimoto Ken Shirabe Toshio Uraoka Source Type: research